15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 9 firms covering Stoke Therapeutics Inc, 8 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets range widely, $25.00 to $60.00 (about 2.4x), a sign of real disagreement on valuation. The average target of $41.22 sits 41% above the current $29.30. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.83 next quarter toward $-3.09 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS9 ratings
Strong Buy
Strong Buy00%
Buy889%
Hold111%
Sell00%
Strong Sell00%
Based on 9 analysts giving stock ratings to Stoke Therapeutics Inc.
As of Jul, 8 of 9 firms rate STOK a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
STOK EPS & revenue forecast
EPS · NEXT QUARTER
$-0.83
Range $-0.97 – $-0.71 · 11 analysts · +27% YoY
Next period, 11 analysts expect Stoke Therapeutics Inc to earn $-0.83 a share (range $-0.97 – $-0.71), versus $-0.65 a year earlier. Full-year consensus is $-3.29, growing to $-3.09 the year after.
REVENUE · NEXT QUARTER
$5.0M
Range $0 – $11.4M · 11 analysts · -53% YoY
Revenue is expected to reach $5.0M (range $0 – $11.4M), -52.8% year-over-year. Full-year consensus is $24.3M, rising to $46.5M next year.
Top analysts covering Stoke Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on STOK.
#1
Yatin Suneja
Guggenheim · Rank #28
Buy
$60.00+104.8% to target
Overall win rate
52%
+ Follow
#2
Andrew Fein
HC Wainwright & Co. · Rank #35
Buy
$35.00+19.5% to target
Overall win rate
46%
+ Follow
#3
Jessica Fye
JP Morgan · Rank #64
Hold
$25.00-14.7% to target
Overall win rate
52%
+ Follow
#4
Laura Chico
Wedbush · Rank #122
Buy
$38.00+29.7% to target
Overall win rate
40%
+ Follow
#5
Keay Nakae
Chardan Capital · Rank #130
Buy
$35.00+19.5% to target
Overall win rate
41%
+ Follow
STOK stock forecast FAQ
What is STOK's average 12-month price target?+
The 9 analysts with a live target average $41.22 for Stoke Therapeutics Inc over the next 12 months, ranging from a $60.00 high to a $25.00 low.
Is STOK stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 9 analyst ratings, 8 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for STOK?+
The Street-high target is $60.00 (Canaccord Genuity), and the Street-low is $25.00 (JP Morgan). The average of all 9 active targets is $41.22.
How many Wall Street analysts cover STOK?+
9 analysts have an active rating on Stoke Therapeutics Inc, and 9 firms carry a live 12-month price target.
Who is the most accurate analyst covering STOK?+
Among analysts who currently cover STOK, Yatin Suneja of Guggenheim has the strongest overall Quantellect track record (Rank #28). Their current call is Buy with a $60.00 target.
What is Stoke Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.83 per share (range $-0.97 – $-0.71) across 11 analysts. Full-year EPS is projected at $-3.29, rising to $-3.09 the following year.
How much revenue is Stoke Therapeutics Inc expected to report next quarter?+
Consensus revenue is $5.0M (range $0 – $11.4M). Full-year revenue is projected at $24.3M, growing to $46.5M next year.
Have analysts been upgrading or downgrading STOK lately?+
As of Jul, 8 of 9 firms rate STOK a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their STOK calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
Goldman Sachs
